ImageneBio Inc (IMA) Stock Analysis

ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.

—

/100 Overall

Calculating score…

Running full analysis

Ready to value this company?
Run a full DCF model with Monte Carlo simulation.

Run DCF Valuation →

📊 Key Metrics

Loading full analysis…

FCF TTM

-$52.1M

Running full 6-factor analysis…

📈 Business Quality

Is this a good business?

Revenue & Net Income

Free Cash Flow

Profit Margins

Shares Outstanding

💰 Capital Allocation

How does management use the money?

💵 Dividends

How much cash comes back to shareholders?

🏷️ Valuation

Is it cheap or expensive?

Multiple	Current	5Y Avg	vs Avg	Signal

🔬 Earnings Quality

Can we trust the numbers?

⚠️ Risk Assessment

What could go wrong?

🚀 Momentum

Is the market moving with or against this stock?

🏛️ Famous Investors (13F)

Do Buffett, Ackman, Loeb or Dalio hold this stock?

📋 Insider Trades (Form 4)

Are the CEO, CFO and directors buying or selling?

🏦 Governance & Ownership

Who owns the company and how much do executives earn?

🚨 Material Events (8-K)

Acquisitions, CEO changes, earnings warnings — what happened?

🥧 Revenue Segments

Where does the revenue actually come from?

🤖 Click Generate Analysis to get an AI-powered interpretation of all financial data.

Three systematic strategies with a public, verifiable month-by-month track record — Premium members see the exact 25 holdings of each basket, updated at every monthly rebalance.